BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9521134)

  • 1. Decline of measles-specific immunoglobulin M antibodies after primary measles, mumps, and rubella vaccination.
    Helfand RF; Gary HE; Atkinson WL; Nordin JD; Keyserling HL; Bellini WJ
    Clin Diagn Lab Immunol; 1998 Mar; 5(2):135-8. PubMed ID: 9521134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin M antibody response to measles virus following primary and secondary vaccination and natural virus infection.
    Erdman DD; Heath JL; Watson JC; Markowitz LE; Bellini WJ
    J Med Virol; 1993 Sep; 41(1):44-8. PubMed ID: 8228936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination.
    Helfand RF; Kebede S; Gary HE; Beyene H; Bellini WJ
    Clin Diagn Lab Immunol; 1999 Mar; 6(2):178-80. PubMed ID: 10066650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to measles-mumps-rubella vaccine in children on dialysis.
    Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
    Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine].
    Pisón Garcés FJ; Galbe Sánchez-Ventura J; Arcauz Eguren P; Aguirre y Dabán C; Mengual Gil J; Larrad Mur L
    Aten Primaria; 1995 Mar; 15(4):235-7. PubMed ID: 7703334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
    Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
    Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response.
    Nakayama T; Urano T; Osano M; Nakagawa M; Maehara N; Sasaki K; Yamamura AM; Makino S
    Microbiol Immunol; 1990; 34(6):497-508. PubMed ID: 2120551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland.
    Davidkin I; Peltola H; Leinikki P; Valle M
    Vaccine; 2000 Jul; 18(27):3106-12. PubMed ID: 10856790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.
    Miller E; Hill A; Morgan-Capner P; Forsey T; Rush M
    Vaccine; 1995 Jun; 13(9):799-802. PubMed ID: 7483800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule.
    Christenson B; Böttiger M
    Vaccine; 1991 May; 9(5):326-9. PubMed ID: 1872016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
    Just M; Berger R; Glück R; Wegmann A
    Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
    King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
    JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles, mumps, and rubella antibodies in vaccinated Baltimore children.
    King JC; Lichenstein R; Feigelman S; Luna C; Permutt TJ; Patel J
    Am J Dis Child; 1993 May; 147(5):558-60. PubMed ID: 8488803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus.
    Weibel RE; Carlson AJ; Villarejos VM; Buynak EB; McLean AA; Hilleman MR
    Proc Soc Exp Biol Med; 1980 Nov; 165(2):323-6. PubMed ID: 7443721
    [No Abstract]   [Full Text] [Related]  

  • 20. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.